Alphamab Oncology
HKEX:9966
Gross Margin
Alphamab Oncology
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | CN |
Market Cap | 4.5B HKD |
Gross Margin |
75%
|
Country | US |
Market Cap | 277.3B USD |
Gross Margin |
66%
|
Country | US |
Market Cap | 164.1B USD |
Gross Margin |
66%
|
Country | US |
Market Cap | 118B USD |
Gross Margin |
87%
|
Country | US |
Market Cap | 108.5B USD |
Gross Margin |
86%
|
Country | AU |
Market Cap | 135.7B AUD |
Gross Margin |
52%
|
Country | US |
Market Cap | 81.8B USD |
Gross Margin |
76%
|
Country | US |
Market Cap | 63.8B USD |
Gross Margin |
22%
|
Country | US |
Market Cap | 43.1B USD |
Gross Margin |
75%
|
Country | US |
Market Cap | 31.7B USD |
Gross Margin |
75%
|
Country | KR |
Market Cap | 37.3T KRW |
Gross Margin |
47%
|
Profitability Report
View the profitability report to see the full profitability analysis for Alphamab Oncology.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Alphamab Oncology's most recent financial statements, the company has Gross Margin of 74.8%.